{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-018166","form_type":"8-K","ticker":null,"cik":"0001102942","company_name":"InnovaQor, Inc.","filed_at":"2023-05-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.949048+00:00","generated_at":"2026-06-14T20:45:50.011515+00:00","sec_items":["1.01","3.02","5.02","5.03","5.07","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"InnovaQor CEO exits; Darrell Peterson named Interim CEO; new preferred stock issuance","bullets":["CEO Sharon Hollis departed May 14; Darrell Peterson appointed Interim President/CEO at $10,000/month salary.","Board expanded to 4; Gerard Dab elected Chairman/Secretary; Francisco Roca III and Peterson join board.","Company sold 300 shares of Series D Preferred Stock to three insiders for $30,000 total proceeds.","Series D carries monthly dividends based on gross sales thresholds (5% above $500k, 10% above $1M, 2.5% above $2M).","Series D ranks senior to common but junior to existing Series A-1, B-1, C-1 preferred; not convertible."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-018166","json":"https://secwatch.observer/filing/0001493152-23-018166.json","markdown":"https://secwatch.observer/filing/0001493152-23-018166.md","text":"https://secwatch.observer/filing/0001493152-23-018166.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T20:45:50.011515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"268521df8b","claim":"Darrell Peterson was elected as Director at InnovaQor, Inc..","evidence_excerpt":"elected Darrell Peterson as a director to fill the vacancy","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3095abbabd","claim":"Francisco Roca III was elected as Director at InnovaQor, Inc..","evidence_excerpt":"Francisco Roca, III","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"3660824c3f","claim":"Gerard Dab was elected as Chairman of the Board and Secretary at InnovaQor, Inc..","evidence_excerpt":"elected Gerad Dab as Chairman of the Board and Secretary of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Chairman of the Board and Secretary"}],"fact_type":"executive_change"},{"claim_id":"42b373e94e","claim":"Sharon Hollis departed as Director at InnovaQor, Inc..","evidence_excerpt":"Prior to the written consent by Epizon Limited, the members of the Board of Directors were Gerard Dab, Justin Doherty and Sharon Hollis.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.9,"family_label":"Executive change","details":[{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"8f744e538c","claim":"Darrell Peterson was named as Interim President and Chief Executive Officer at InnovaQor, Inc..","evidence_excerpt":"named Mr. Peterson to be Interim President and Chief Executive Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"named"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6015962d68c53b31abe2c1f4c887cbef35c667a5","claim":"InnovaQor, Inc.: Filed Certificate of Designation to authorize issuance of up to 500 shares of Series D Preferred Stock (effective 2023-05-12).","evidence_excerpt":"On May 12, 2023, the Company filed a Certificate of Designation with the Secretary of State of the State of Nevada to authorize the issuance of up to 500 shares of Series D Preferred Stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-12"}],"fact_type":"governance_change"},{"claim_id":"0540dd80fef5f9f514c6bb0bfb72d0ee8b87d970","claim":"InnovaQor, Inc. entered into Securities Purchase Agreements with Alcimede Limited, Pathlogic Limited, and Hollis Capital Holdings, LLC valued at Total proceeds of $30,000 for the issuance of 100 shares of Series D Non-Convertible Preferred Stock (effective 2023-05-12).","evidence_excerpt":"On May 12, 2023, Rennova Health, Inc. (the “Company”) entered into Securities Purchase Agreements, dated as of May 12, 2023 (the “Purchase Agreements”), with Alcimede Limited (“Alcimede”), Pathlogic Limited (“Pathlogic”) and Hollis Capital Holdings, LLC (“Hollis Capital”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1102942/000149315223018166/0001493152-23-018166-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Alcimede Limited, Pathlogic Limited, and Hollis Capital Holdings, LLC"},{"label":"Value","value":"Total proceeds of $30,000 for the issuance of 100 shares of Series D Non-Convertible Preferred Stock"},{"label":"Effective","value":"2023-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}